Oruka Therapeutics, Inc. (ORKA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 104.86 |
| Open | 103.86 |
| Day High | 108.49 |
| Day Low | 103.86 |
| 52-Week High | 115.52 |
| 52-Week Low | 14.34 |
| Volume | 935,783 |
| Average Volume | 1.22M |
| Market Cap | 6.51B |
| PE | -55.65 |
| EPS | -1.94 |
| Moving Average 50 Days | 91.43 |
| Moving Average 200 Days | 54.82 |
| Change | 3.1 |
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
GlobeNewswire Inc.
Feb 09, 2026 12:00 PM GMT
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases inc
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases inc